Search

The new coronavirus SARS-CoV-2 is causing a huge impact on health, economy, and social dynamics. The world is facing an emerging viral disease for which no specific treatment is available, and many aspects of the clinical behavior of the disease are still unknown, which makes the diagnosis and management a big challenge. Various neurological manifestations have been described and associated with SARS-CoV-2 infection. Stroke occurs in up to 6% of all patients with COVID-19, a figure that becomes significant given the large number of patients diagnosed to date. The clinical characteristics, presentation, evolution, and prognosis of these patients seem to have peculiarities that have not been seen in previous forms of stroke. Every time younger patients are observed, without a medical history, without infectious symptoms, with serious neurological results that pose a challenging and difficult approach. This review synthesizes the information available on the clinical characteristics and the proposals for its management., (Copyright © 2020 Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Publicado por Elsevier España, S.L.U. All rights reserved.)

Unlabelled: Hybrid imaging, such as SPECT/CT, is used in routine clinical practice, allowing coregistered images of the functional and structural information provided by the two imaging modalities. However, this multimodality imaging may mean that patients are exposed to a higher radiation dose than those receiving SPECT alone., Objectives: The study aimed to determine the radiation exposure of patients who had undergone SPECT/CT examinations and to relate this to the Background Equivalent Radiation Time (BERT)., Methods: 145 SPECT/CT studies were used to estimate the total effective dose to patients due to both radiopharmaceutical administrations and low-dose CT scans. The CT contribution was estimated by the Dose-Length Product method. Specific conversion coefficients were calculated for SPECT explorations., Results: The radiation dose from low-dose CTs ranged between 0.6 mSv for head and neck CT and 2.6 mSv for whole body CT scan, representing a maximum of 1 year of background radiation exposure. These values represent a decrease of 80-85% with respect to the radiation dose from diagnostic CT. The radiation exposure from radiopharmaceutical administration varied from 2.1 mSv for stress myocardial perfusion SPECT to 26 mSv for gallium SPECT in patients with lymphoma. The BERT ranged from 1 to 11 years., Conclusions: The contribution of low-dose CT scans to the total radiation dose to patients undergoing SPECT/CT examinations is relatively low compared with the effective dose from radiopharmaceutical administration. When a CT scan is only acquired for anatomical localization and attenuation correction, low-dose CT scan is justified on the basis of its lower dose.